# Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

> **NCT04006210** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NeuroDerm Ltd.** · enrollment: 381 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **COMBINATION_PRODUCT:** ND0612 Solution for SC infusion
- **COMBINATION_PRODUCT:** Placebo for SC infusion
- **DRUG:** Oral IR-LD/CD
- **DRUG:** Placebo for Oral IR-LD/CD

## Key facts

- **NCT ID:** NCT04006210
- **Lead sponsor:** NeuroDerm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-30
- **Primary completion:** 2022-11-01
- **Final completion:** 2027-02
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006210, "Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04006210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*